{
  "meta": {
    "timestamp": "2025-01-06T12:30:49.210482",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "ATAI Life Sciences NV",
      "symbol": "ATAI",
      "analysis": {
        "historical": {
          "risk_score": 70,
          "key_risks": [
            "Regulatory challenges due to classification of psychedelic compounds as controlled substances",
            "Clinical trial risks with potential failures or delays impacting valuation and funding",
            "Financial sustainability concerns due to reliance on external funding and lack of profitability",
            "Public perception risks related to the controversial nature of psychedelic therapies"
          ],
          "controversies": [
            "Use of psychedelics in medicine remains controversial, affecting investor sentiment and market acceptance",
            "Ethical concerns surrounding the use of controlled substances for therapeutic purposes"
          ],
          "environmental_issues": [],
          "social_issues": [
            "Addressing unmet mental health needs aligns with societal awareness, but controversial therapies may pose reputational risks"
          ],
          "governance_issues": [],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Atai Life Sciences N.V. - AnnualReports.com",
              "snippet": "atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. They founded atai in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, as well as the emergence of therapies that previously may have been overlooked or underused, including psychedelic compounds and \u2026",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV public perception psychedelic medicine",
              "retrieved_at": "2025-01-06T19:30:32.500157+00:00",
              "published_date": null,
              "source_hash": "a76c0ae6b9835055df4a6d297ee7ece0"
            },
            {
              "url": "",
              "title": "Home - atai Life Sciences",
              "snippet": "atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, with offices in New York, San Diego and Berlin. Our vision is to heal mental health disorders so that everyone everywhere can live a more fulfilled life.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV public perception psychedelic medicine",
              "retrieved_at": "2025-01-06T19:30:32.499980+00:00",
              "published_date": null,
              "source_hash": "ffcab955ade443e057b131314c34f3df"
            },
            {
              "url": "",
              "title": "Growth Strategy and Future Prospects of ATAI Life Sciences",
              "snippet": "Regulatory Hurdles: One of the primary challenges facing ATAI Life Sciences is navigating the complex regulatory landscape governing pharmaceuticals and mental health treatments. As the company advances its pipeline of novel therapies, it must ensure compliance with stringent regulatory requirements and demonstrate the safety and efficacy of ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV regulatory challenges psychedelic therapies",
              "retrieved_at": "2025-01-06T19:30:20.457884+00:00",
              "published_date": null,
              "source_hash": "46825e0b50ca9c8caab791e9f146300b"
            },
            {
              "url": "",
              "title": "Risk adjusted net present value: What is the current valuation of Atai ...",
              "snippet": "Oncology R&D: emerging therapies and new challenges ... Atai Life Sciences NV's RL-007. Buy the Model. Data Insights The gold standard of business intelligence. Find out more Related Company Profiles. Atai Life Sciences NV View all. The revenue for RL-007 is expected to reach an annual total of $143 mn by 2038 in the US based off GlobalData's ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV regulatory challenges psychedelic therapies",
              "retrieved_at": "2025-01-06T19:30:20.457897+00:00",
              "published_date": null,
              "source_hash": "dda567b2e0630342b09736dbeee6cf17"
            },
            {
              "url": "",
              "title": "atai Life Sciences advances therapeutic pipeline in Q3 with FDA ...",
              "snippet": "atai Life Sciences (NASDAQ:ATAI, ETR:9VC), a biopharmaceutical company targeting mental health disorders, advanced its pipeline of innovative therapies during the third quarter of 2024. Notably, the US Food and Drug Administration approved an investigational new drug application for for VLS-01, atai's buccal film formulation of DMT.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV regulatory challenges psychedelic therapies",
              "retrieved_at": "2025-01-06T19:30:20.457908+00:00",
              "published_date": null,
              "source_hash": "9e6c2f49a9360f5d458a0a452397f6bf"
            },
            {
              "url": "",
              "title": "Atai Life Sciences N.V. - 10Q - Quarterly Report - Fintel",
              "snippet": "Atai Life Sciences N.V. - 10Q - Quarterly Report - November 13, 2024 ... and we cannot give any assurance that any of our product candidates will be successfully developed and/or receive regulatory approval, which is necessary before they can be commercialized; research and development of drugs targeting the central nervous system, or CNS, is ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV regulatory challenges psychedelic therapies",
              "retrieved_at": "2025-01-06T19:30:20.457919+00:00",
              "published_date": null,
              "source_hash": "1f846384985ce9956529d04d693a04b2"
            },
            {
              "url": "",
              "title": "Atai Life Sciences N.V. (ATAI) Company Profile & Overview - Stock Analysis",
              "snippet": "Company profile for Atai Life Sciences N.V. (ATAI) with a description, list of executives, contact details and other key facts. ... VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV regulatory challenges psychedelic therapies",
              "retrieved_at": "2025-01-06T19:30:20.457928+00:00",
              "published_date": null,
              "source_hash": "a565ba3d05149b4a878a114077da7cbd"
            },
            {
              "url": "",
              "title": "atai Life Sciences | Psychedelic Invest",
              "snippet": "Atai is a biotechnology company founded in 2018 in response to the clear and growing unmet needs of mental health patients worldwide. Atai is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Aai's business model combines funding, technology, scientific and regulatory expertise ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV regulatory challenges psychedelic therapies",
              "retrieved_at": "2025-01-06T19:30:20.457939+00:00",
              "published_date": null,
              "source_hash": "c9db2aa0e6849870fab76b0791b10aea"
            },
            {
              "url": "",
              "title": "Atai Life Sciences N.V. (ATAI) - Stock Analysis",
              "snippet": "Get a real-time Atai Life Sciences N.V. (ATAI) stock price quote with breaking news, financials, statistics, charts and more. ... Psychedelic Stock Deep Dive: Atai Life Sciences. ... Targeting Schizophrenia Subpopulation With No FDA Approved Therapies. Atai Life Sciences is advancing RL-007 for the treatment of cognitive impairment associated ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV regulatory challenges psychedelic therapies",
              "retrieved_at": "2025-01-06T19:30:20.457951+00:00",
              "published_date": null,
              "source_hash": "151367826caa9aef459d616b7c7b9b0d"
            },
            {
              "url": "",
              "title": "A Brief History of ATAI Life Sciences - CBM",
              "snippet": "[cbm_blg_rlnkng]ATAI Life Sciences is a pioneering biotech company at the forefront of cutting-edge research and innovation in the field of mental health. Founded in 2018, ATAI is dedicated to revolutionizing the treatment of mental health disorders through the development of psychedelic compounds and therapies. With a",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV regulatory challenges psychedelic therapies",
              "retrieved_at": "2025-01-06T19:30:20.457961+00:00",
              "published_date": null,
              "source_hash": "5a488a1ba0ca8a6b5f37d1d549e3cc27"
            },
            {
              "url": "",
              "title": "The ATAI Life Sciences NV Rollercoaster: What's Behind the Latest ATAI Stock Fluctuation?",
              "snippet": "ATAI Life Sciences NV (ATAI) stock saw a modest uptick, ending the day at $1.77 which represents a slight increase of $0.17 or 10.63% from the prior close of $1.6. The stock opened at $1.65 and touched a low of $1.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV public perception psychedelic medicine",
              "retrieved_at": "2025-01-06T19:30:34.814007+00:00",
              "published_date": "2025-01-04T13:09:00+00:00",
              "source_hash": "8e23973adfa1f9b81a6513c1183717a7"
            },
            {
              "url": "",
              "title": "Thiel-Backed Psychedelic Firm Atai to Buy Stake in Beckley",
              "snippet": "(Bloomberg) -- Atai Life Sciences NV agreed to acquire a stake in ... in the company complements Atai's portfolio of psychedelic-based therapies, which are used to treat mental disorders ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV regulatory challenges psychedelic therapies",
              "retrieved_at": "2025-01-06T19:30:23.978035+00:00",
              "published_date": "2024-01-04T12:49:00+00:00",
              "source_hash": "0c1f7812d950f8c5590ab19428790ad6"
            },
            {
              "url": "",
              "title": "ATAI Life Sciences NV",
              "snippet": "We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV public perception psychedelic medicine",
              "retrieved_at": "2025-01-06T19:30:34.814062+00:00",
              "published_date": "2024-11-11T12:30:00+00:00",
              "source_hash": "a1ea1e180d1746348fcf59ac6f2f6acb"
            },
            {
              "url": "",
              "title": "atai Life Sciences is developing innovative therapies for mental health disorders",
              "snippet": "atai Life Sciences (NASDAQ:ATAI, ETR:9VC) shares should move higher on a slew of Phase 2 and 3 data readouts in 2025 from across its pipeline of innovative psychedelic therapies, analysts at Jefferies. Following the release of atai's third quarter ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV regulatory challenges psychedelic therapies",
              "retrieved_at": "2025-01-06T19:30:23.978055+00:00",
              "published_date": "2024-05-15T19:55:00+00:00",
              "source_hash": "ff611a80517e810fb182edb60ba90fbe"
            },
            {
              "url": "",
              "title": "atai invests $50m in Beckley Psytech",
              "snippet": "Beckley Psytech has announced that it has received substantial strategic investment from Germany-based atai Life Sciences ... Britain as a leading hub for psychedelic research - the deal comprises ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV regulatory challenges psychedelic therapies",
              "retrieved_at": "2025-01-06T19:30:23.978063+00:00",
              "published_date": "2025-01-03T00:00:00+00:00",
              "source_hash": "32f0c81ccd98cc68a65805c6d3c6e184"
            },
            {
              "url": "",
              "title": "atai Life Sciences Announces Key Clinical Pipeline and Corporate ...",
              "snippet": "About atai Life Sciences. ... and our preclinical programs may experience delays or may never advance to clinical trials; we rely on third parties to assist in conducting our clinical trials and some aspects of our research and preclinical testing, and those clinical trials, including progress and related milestones, may be impacted by several ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV clinical trial failures or delays",
              "retrieved_at": "2025-01-06T19:30:26.326620+00:00",
              "published_date": null,
              "source_hash": "d98036451821d7b6ddd53ced8e40df90"
            },
            {
              "url": "",
              "title": "Home - atai Life Sciences",
              "snippet": "atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference. NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) \u2014 atai Life Sciences (NASDAQ: ATAI) (\"atai\" or \"Company\"), a clinical-stage biopharmaceutical company\u2026",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV clinical trial failures or delays",
              "retrieved_at": "2025-01-06T19:30:26.326711+00:00",
              "published_date": null,
              "source_hash": "3700aa926445c9d233f1d9bafd14c73e"
            },
            {
              "url": "",
              "title": "ATAI Life Sciences NV - Drug pipelines, Patents, Clinical trials - Synapse",
              "snippet": "NEW YORK and BERLIN, Oct. 15, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (\"atai\" or \"Company\"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that Srinivas Rao, M.D., Ph.D., the Company's Co-founder and Co-CEO, is scheduled to participate in the 2024 Maxim Healthcare Virtual Summit taking place ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV clinical trial failures or delays",
              "retrieved_at": "2025-01-06T19:30:26.326732+00:00",
              "published_date": null,
              "source_hash": "406a0669cc4c7e2ff95cf0f0b3bc6b8f"
            },
            {
              "url": "",
              "title": "atai Life Sciences launches TryptageniX to further expand atai's robust ...",
              "snippet": "About atai Life Sciences. ... and our preclinical programs may experience delays or may never advance to clinical trials; we rely on third parties to assist in conducting our clinical trials and some aspects of our research and preclinical testing, and those clinical trials, including progress and related milestones, may be impacted by several ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV clinical trial failures or delays",
              "retrieved_at": "2025-01-06T19:30:26.326744+00:00",
              "published_date": null,
              "source_hash": "d5090072f16861b7f9569fc707d19686"
            },
            {
              "url": "",
              "title": "Risk adjusted net present value: What is the current valuation of Atai ...",
              "snippet": "RL-007 is a small molecule commercialized by Atai Life Sciences, with a leading Phase II program in Cognitive Impairment Associated With Schizophrenia (CIAS). According to Globaldata, it is involved in 5 clinical trials, of which 4 were completed, and 1 is ongoing.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV clinical trial failures or delays",
              "retrieved_at": "2025-01-06T19:30:26.326755+00:00",
              "published_date": null,
              "source_hash": "e595f6a2dcc7c3caeca1aebd71c18ef0"
            },
            {
              "url": "",
              "title": "Positive Outlook for ATAI Life Sciences Amidst Upcoming Clinical Trials ...",
              "snippet": "ATAI Life Sciences (ATAI) Company Description: ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV clinical trial failures or delays",
              "retrieved_at": "2025-01-06T19:30:26.326765+00:00",
              "published_date": null,
              "source_hash": "de27efcf1f3018143ecb6ce3c56f11c2"
            },
            {
              "url": "",
              "title": "atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 ...",
              "snippet": "NEW YORK and BERLIN, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Today, atai Life Sciences N.V. (Nasdaq: ATAI) (\"atai\"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the initiation of its Phase 2b proof-of-concept clinical trial for RL-007 for Cognitive Impairment Associated with ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV clinical trial failures or delays",
              "retrieved_at": "2025-01-06T19:30:26.326774+00:00",
              "published_date": null,
              "source_hash": "1e8e6d87daf8314baace532cf00efc59"
            },
            {
              "url": "",
              "title": "atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept ...",
              "snippet": "NEW YORK and BERLIN, Oct. 18, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences (\"atai\" or the \"Company\") (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders today announced the initiation of the Phase 1 proof-of-concept (PoC) clinical trial of intranasal INB-01, a sol-gel ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV clinical trial failures or delays",
              "retrieved_at": "2025-01-06T19:30:26.326784+00:00",
              "published_date": null,
              "source_hash": "138ad4fec74c94c1562290770f988fd7"
            },
            {
              "url": "",
              "title": "Atai Life Sciences Announces First Participant Dosed in Phase 1b Trial ...",
              "snippet": "NEW YORK and BERLIN, March 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (\"atai\" or \"Company\"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the first healthy participant has been dosed in the Phase 1b trial of VLS-01, an oral transmucosal ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV clinical trial failures or delays",
              "retrieved_at": "2025-01-06T19:30:26.326793+00:00",
              "published_date": null,
              "source_hash": "cead172dba6e5a1876133edde3c46eaf"
            },
            {
              "url": "",
              "title": "ATAI Life Sciences: Buy Rating Affirmed Amid Promising Pipeline and ...",
              "snippet": "ATAI Life Sciences (ATAI) Company Description: ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV clinical trial failures or delays",
              "retrieved_at": "2025-01-06T19:30:26.326802+00:00",
              "published_date": null,
              "source_hash": "0cc8b67ce8f95815ee4caaac3c9bc7b3"
            },
            {
              "url": "",
              "title": "ATAI Life Sciences N.V.",
              "snippet": "ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV clinical trial failures or delays",
              "retrieved_at": "2025-01-06T19:30:28.919637+00:00",
              "published_date": "2018-10-03T17:58:00+00:00",
              "source_hash": "ed62ceb0857637a9f9afcbc7f292623f"
            },
            {
              "url": "",
              "title": "ATAI Life Sciences (NASDAQ:ATAI) Stock, Short Interest Report",
              "snippet": "Short interest in ATAI Life Sciences NV (NASDAQ:ATAI) increased during the last reporting period, rising from 9.43M to 9.87M. This put 7.71% of the company's publicly available shares short.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV public perception psychedelic medicine",
              "retrieved_at": "2025-01-06T19:30:34.814074+00:00",
              "published_date": "2024-10-24T14:21:00+00:00",
              "source_hash": "2a2bd208f01d8542501d16c9054dd4b4"
            },
            {
              "url": "",
              "title": "ATAI Stock Earnings: ATAI Life Sciences Misses EPS for Q2 2024",
              "snippet": "ATAI Life Sciences reported earnings per share of -36 cents. This was below the analyst estimate for EPS of -16 cents. The company reported revenue of $273,000.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV clinical trial failures or delays",
              "retrieved_at": "2025-01-06T19:30:28.919654+00:00",
              "published_date": "2024-08-13T18:08:00+00:00",
              "source_hash": "9d53bae7ed4b6e8ecdddc96b8610f9b9"
            },
            {
              "url": "",
              "title": "Atai Life Sciences N.V. (ATAI) - Yahoo Finance",
              "snippet": "Find the latest Atai Life Sciences N.V. (ATAI) stock quote, history, news and other vital information to help you with your stock trading and investing. ... and ELE-101, a serotonergic psychedelic ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV public perception psychedelic medicine",
              "retrieved_at": "2025-01-06T19:30:32.499846+00:00",
              "published_date": null,
              "source_hash": "8b804f87b6e9ab91f1759023dddeab44"
            },
            {
              "url": "",
              "title": "Atai Life Sciences Goes Public; Now the Largest Publicly Traded ...",
              "snippet": "NEW YORK and BERLIN, Oct. 15, 2024 (GLOBE NEWSWIRE) \u2014 atai Life Sciences (NASDAQ: ATAI) (\"atai\" or \"Company\"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that Srinivas Rao, M.D., Ph.D., the Company's Co-founder and Co-CEO, is scheduled to participate in ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV public perception psychedelic medicine",
              "retrieved_at": "2025-01-06T19:30:32.500010+00:00",
              "published_date": null,
              "source_hash": "5445cfc93423d7aa449b89715a2d4f80"
            },
            {
              "url": "",
              "title": "Atai Life Sciences N.V. (ATAI) - Stock Analysis",
              "snippet": "Get a real-time Atai Life Sciences N.V. (ATAI) stock price quote with breaking news, financials, statistics, charts and more. ... Psychedelic Stock Deep Dive: Atai Life Sciences. After the FDA's rejection of Lykos Therapeutics' NDA for MDMA therapy, we take a more complete look at major psychedelic stocks. Atai Life Sciences is an early mover ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV public perception psychedelic medicine",
              "retrieved_at": "2025-01-06T19:30:32.500044+00:00",
              "published_date": null,
              "source_hash": "522883d6a9e7695c625568726738f426"
            },
            {
              "url": "",
              "title": "ATAI Life Sciences NV, ATAI:NMQ summary - FT.com - Financial Times",
              "snippet": "On Friday, ATAI Life Sciences NV (ATAI:NMQ) closed at 1.19, 15.53% above the 52 week low of 1.03 set on Oct 11, 2024. 52-week range. Today. 1.03 Oct 11 2024 2.85 Apr 04 2024. Short selling activity. Low. Med. High. ... Investors pile into psychedelic drug start-ups tackling mental health.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV public perception psychedelic medicine",
              "retrieved_at": "2025-01-06T19:30:32.500070+00:00",
              "published_date": null,
              "source_hash": "464b0fb8e25a40aa7af4616dadf310cd"
            },
            {
              "url": "",
              "title": "S-1/A - SEC.gov",
              "snippet": "ATAI Life Sciences US Inc. 180 Varick Street . New York, New York 10014 ... Approximate date of commencement of proposed sale to the public: ... 2017, between National University Corporation Chiba University and Perception Neurosciences, Inc., as amended by Amendment No. 1, dated as of August 7, 2018, the Second Amendment, dated as of March 17 ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV public perception psychedelic medicine",
              "retrieved_at": "2025-01-06T19:30:32.500093+00:00",
              "published_date": null,
              "source_hash": "4448f9dd806d25ddb5c55e97e33e6fac"
            },
            {
              "url": "",
              "title": "Atai Life Sciences N.V. (ATAI) | AAII Stock Evaluator - Investor Education",
              "snippet": "ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London. Commentary & Analysis Stock Grade Focus",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV public perception psychedelic medicine",
              "retrieved_at": "2025-01-06T19:30:32.500115+00:00",
              "published_date": null,
              "source_hash": "345f7f1ad211cb5296b307dd526bcdea"
            },
            {
              "url": "",
              "title": "ATAI - ATAI Life Sciences NV News - Morningstar",
              "snippet": "Read about ATAI Life Sciences NV (ATAI:XNAS) stock and today's latest news and financial updates. ... Psychedelic-medicine stocks drop after ecstasy's rocky day at the FDA",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV public perception psychedelic medicine",
              "retrieved_at": "2025-01-06T19:30:32.500136+00:00",
              "published_date": null,
              "source_hash": "a5e594045ce68a3c10a48adc06e06829"
            },
            {
              "url": "",
              "title": "The ATAI Life Sciences NV Rollercoaster: What's Behind the Latest ATAI ...",
              "snippet": "ATAI Life Sciences NV (ATAI) Stock Trading Recap. On Friday, ATAI Life Sciences NV (ATAI) stock saw a modest uptick, ending the day at $1.77 which represents a slight increase of $0.17 or 10.63% from the prior close of $1.6. The stock opened at $1.65 and touched a low of $1.59 during the day, reaching a high of $1.77.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV public perception psychedelic medicine",
              "retrieved_at": "2025-01-06T19:30:32.500183+00:00",
              "published_date": null,
              "source_hash": "9efd8ce7ed7ab03353fb13e5ff6728c6"
            },
            {
              "url": "",
              "title": "ATAI Life Sciences N.V.",
              "snippet": "1 Day ATAI -7.53% DJIA 0.11% Russell 2K -0.94% Health Care/Life Sciences -1.00%",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV public perception psychedelic medicine",
              "retrieved_at": "2025-01-06T19:30:34.814050+00:00",
              "published_date": "2024-11-14T00:58:00+00:00",
              "source_hash": "1802c79f27156ac7bbf9d0fae8c204fd"
            },
            {
              "url": "",
              "title": "Thiel-Backed Psychedelic Firm Atai to Buy Stake in Beckley",
              "snippet": "Atai Life Sciences NV agreed to acquire a stake in smaller rival Beckley Psytech to expand its portfolio of drug candidates for the treatment of mental health conditions. The German psychedelic ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "ATAI Life Sciences NV ATAI Life Sciences NV public perception psychedelic medicine",
              "retrieved_at": "2025-01-06T19:30:34.814085+00:00",
              "published_date": "2024-01-04T12:49:00+00:00",
              "source_hash": "471dc2a2fb776c4fb3974057abaeedeb"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "ATAI Life Sciences NV regulatory challenges psychedelic therapies",
              "rationale": "Investigate regulatory hurdles and legal risks associated with psychedelic-based therapies",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "ATAI Life Sciences NV clinical trial failures or delays",
              "rationale": "Assess risks related to the success of ongoing clinical trials, which are critical for the company's future",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "ATAI Life Sciences NV public perception psychedelic medicine",
              "rationale": "Explore controversies or ethical concerns surrounding the use of psychedelics in mental health treatment",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T12:30:49.210490",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}